Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors
Background. Programmed death 1 (PD-1) is a co-receptor which is located at the surface of cells like natural killer, monocytes, T and B cells. It has two ligands including programmed death ligand-1 (PD-L1) and ligand-2 (PD-L2). T cell functions are inhibited by activation of PD-1/PD-L1 pathwa...
Saved in:
| Main Authors: | Seher Şener, Aylar Poyraz, Arzu Okur, Faruk Güçlü Pınarlı, Ceyda Karadeniz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hacettepe University Institute of Child Health
2021-10-01
|
| Series: | The Turkish Journal of Pediatrics |
| Subjects: | |
| Online Access: | https://turkjpediatr.org/article/view/359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis
by: Tzu-Rong Peng, et al.
Published: (2023-11-01) -
Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
by: Hanan R. Nada, et al.
Published: (2025-01-01) -
Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
by: T. N. Sotnikova, et al.
Published: (2023-07-01) -
Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study
by: Junjie Bai, et al.
Published: (2025-07-01) -
The prognostic implications of podoplanin in cancer‐associated fibroblasts and PD‐L1 expression in high‐grade neuroendocrine carcinoma of the lung
by: Tatsuya Miyamoto, et al.
Published: (2024-12-01)